Shots:

• The P-III GY004 study involves assessing of cediranib + Lynparza vs Lynparza as monothx. vs standard platinum-based CT in patients with recurrent platinum-sensitive OC- fallopian tube- or primary peritoneal cancer patients- with/without a BRCA mutation
• The P-III GY004 study resulted in not meeting its 1EPs in IIT population i.e. an improvement in PFS when cediranib added to Lynparza- safety & tolerability profile is consistent with the known profile of individual therapy
•  Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation). Cediranib is an oral VEGFR inhibitor- targeting the growth of blood vessels supporting tumor growth

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca